Endothelin-1 (ET-1) exhibits vasoconstricting and growth-promoting properties in vascular smooth muscle. Whether ET-1 has mitogenic properties in uterine smooth muscle cells, and which ET receptor subtype mediates this response, is unknown. The present study was undertaken to examine the proliferative potential of the ET family on human myometrial cells in culture. ET-1 stimulated DNA synthesis and proliferation of myometrial cells. The absence of a stimulating effect of endothelin-3 (ET-3) or the ET B agonist sarafotoxin 6c (S6c) was observed. The proliferative effect of 100nM ET-1 was blocked by the two ET A antagonists (BQ 123 and FR 139317), whereas the ET B antagonist IRL 1038 was ineffective. These data indicated that ET-1-induced DNA synthesis was mediated only by the ET A receptor subtype. Pertussis toxin (PTX) pretreatment completely abolished this effect, indicating that this pathway was coupled to the ET A receptor via the G i protein family. PTX treatment partially decreased serum-induced DNA synthesis. This suggests that some factors from serum may operate via the G-protein in initiation of mitogenesis. Insulin-like growth factors (IGFs), epidermal growth factor (EGF) and insulin were found to be mitogens in the absence of serum, and they had no potentiating effect on ET-1-induced DNA synthesis. In the presence of 0.5% serum, EGF alone caused a weak increase in DNA synthesis, while all the growth factors were able to reduce the proliferative effect of ET-1. These findings on human myometrial cells in culture raise the possibility that, under certain conditions, ET-1 may function as a positive or as a negative modulator of smooth muscle proliferation.
Introduction
Endothelin-1 (ET-1) is a 21-amino acid vasoconstrictor peptide originally isolated from endothelial cells. Further studies have revealed the existence of two additional isopeptides, endothelin-2 (ET-2) and endothelin-3 (ET-3), which differ from ET-1 by two and six amino acids respectively. The three endothelin isopeptides share close resemblance, both in structure and biological activity, to the sarafotoxins isolated from venom of the snake Atractaspis engaddensis (for review see Rubanyi and Polakoff, 1994) . In addition to their contractile action on smooth muscle, numerous studies described various biological activities of the ET family, including the mitogenic effect of ET-1 on smooth muscle cells (Battistini et al., 1993) .
Based on pharmacological and molecular experiments, the existence of two distinct ET receptor subtypes was demonstrated. These receptors contain seven hydrophobic transmembraneous domains common to the superfamily of G-proteincoupled receptors. The ET A subtype is ET-1-and ET-2-selective (Arai et al., 1990) , whereas the ET B subtype shows equipotent affinity for all three endothelins and for sarafotoxins (Sakurai et al., 1990) .
Both ET A and ET B receptors are found in the human myometrium. However, it has been demonstrated recently that only ET A receptors mediate the contractile effect of ET-1 in this tissue (Bacon et al., 1995; Héluy et al., 1995a; Osada et al., 1997) and that ET B receptors play no role in these responses. At the present time, the physiological function of ET B receptors in myometrium is still unknown. Since ET-1 has mitogenic properties in vascular smooth muscle cells mediated by selective stimulation of ET B receptors (Eguchi et al., 1994) , it is possible that the ET B receptors in the human myometrium may contribute to uterine growth associated with diverse physiological and pathophysiological situations. However, no data are available concerning a potential growthpromoting role in human myometrial cells. Accordingly, the present study was undertaken to determine whether ET-1, ET-3 or sarafotoxin are mitogenic for human myometrial cells. To ascertain the nature of the receptor involved in ET-1-induced proliferation of these cells, the effects of ET receptor antagonists were studied. Bordetella pertussis toxin (PTX) was used to determine the role of PTX-sensitive Gproteins in ET-1-induced proliferation. The modulating effect of various growth factors was also investigated.
Materials and methods

Reagents
Dulbecco's modified Eagle's medium (DMEM) and fetal calf serum (FCS) were from Gibco Life Tecnologies (Cergy-Pontoise, France). A monoclonal antibody against smooth muscle α-actin was obtained from Novacostra Laboratories Ltd (Newcastle-uponTyne, UK). [6-3 H] thymidine (25 Ci/mmol) was obtained from Amersham International (Chalfont, Buckinghamshire, UK). ET-1, ET-3, sarafotoxin 6c (S6c) and the ET receptor antagonists BQ-123, FR 139317 and IRL 1038 were from Neosystem Laboratoire (Strasbourg, France). PTX was from List Biological Laboratories (Campbell, CA, USA). Epidermal growth factor (EGF) and insulin growth factors (IGFs) were purchased from Chemicon International (Temecula, CA, USA). Other drugs and chemicals used were of the highest quality available from Sigma Chemical (St Louis, MO, USA).
Myometrial cell culture
Human myometrium was obtained from women (34-46 years old) undergoing hysterectomy for benign gynaecological indications. None of the patients was under hormonal treatment at the time of surgery. Tissue samples were excised in the uterine corpus from normal muscle in areas free of macroscopically visible anomalies. This study was approved by the Comité Consultatif de Protection des Personnes dans la Recherche Biomédicale (Paris-Cochin, France). The stage of the menstrual cycle was estimated histologically by dating the endometrium according to the criteria of Noyes et al. (1950) . The biopsy specimens (five from the proliferative and five from the secretory phase of the menstrual cycle) were taken from the external muscle layer to avoid contamination by endometrium. After collection, the tissues were placed in DMEM supplemented by 100 IU/ml penicillin and 100 µg/ml streptomycin. Myometrial cells were prepared as previously described (Cavaillé et al., 1995) . Briefly, 20 muscle explants (ഛ1 mm 3 ) were placed into 6 cm dishes with 1 ml DMEM supplemented with 20% FCS and antibiotics and maintained at 37°C in a humidified atmosphere of 95% air/5% CO 2 . After 3 days, 2 ml of DMEM was added. When cells could be observed growing out from the explants ( Figure 1A ), the culture medium was replaced by 5 ml DMEM containing 10% FCS. Cells were confluent 21 days after tissue collection and then were subcultured every 7 days by trypsinization. Figure 1B shows the typical shape of confluent cultured human myometrial cells at passage 4, 7 days after plating. Cells were arranged in bundles forming a highly organized hill-and-valley structure, which is characteristic of smooth muscle cells in culture. All experiments were performed between passages 3-9, with no noticeable difference in results observed with cells from individual passages, or with cells obtained from different uteri at either the proliferative or the secretory phases of the menstrual cycle. Myometrial cells were identified by their positive reaction with monoclonal antibody against smooth muscle α-actin, diluted 1:20 ( Figure 1C) .
[ 3 H]-thymidine incorporation
Myometrial cells (50 000 cells/well) were cultured to subconfluence in 24-well dishes in the presence of 10% FCS for 24 h. The cells in exponential growth were then transferred into serum-deprived media for 72 h to achieve quiescence. The medium was also free of Phenol Red because of its potential oestrogenic action. The incubation period required to induce quiescence in myometrial cells was defined in separate experiments in which cells were incubated in serum-free DMEM for various times, and viable cells were counted. Under these conditions, myometrial cells were determined to be quiescent after 48 h incubation and remained in a non-catabolic state for at least 96 h (data not shown). When quiescence had been reached, the media were removed and cells were washed and incubated in either serumfree or 0.5% FCS-supplemented media in the presence of various concentrations of ET-1 and/or either ET receptor antagonists or growth factors for 48 h. In some incubations, ET-1 was replaced by ET-3 or the ET B agonist, sarafotoxin 6c (S6c). In an additional experiment, myometrial cells were pretreated with PTX (0.5 µg/ml) for 24 h prior to incubation with ET-1. Control cells were cultured with DMEM containing either 0 or 0.5% FCS (as a negative control) or DMEM containing 10% FCS (as a positive control). [ 3 H]-thymidine (0.4 µCi/well) was added during the final 24 h of incubation. After incubation, cells were washed twice with phosphate-buffered saline (PBS) without Mg 2ϩ and Ca 2ϩ , fixed with 5% trichloroacetic acid, washed twice with 100% ethanol and solubilized with 0.5 N sodium hydroxide. Cell-associated radioactivity was measured by scintillation counting. All experiments were performed in triplicate.
Cell number determinations
Cells were made quiescent by a 3 day incubation in serum-free DMEM, and were incubated in the presence of various factors as Figure 2 . Effect of endothelin-1 (ET-1), endothelin-3 (ET-3) and sarafotoxin 6c (S6c) on proliferation of human myometrial cells. Cells (50 000 cells/well) were cultured in either serum-free medium (NA, no addition) or medium containing 0.5% serum and 10% serum. (A) Cells were incubated for 48 h with 100 nM ET-1, ET-3 or S6c in either serum-free medium, or with 0.5% serum. [ 3 H]-thymidine incorporation was determined as in Materials and methods. Data are means Ϯ SE for at least three independent experiments, performed in triplicate. (B) Cells were incubated for 72 h with 100 nM ET-1, ET-3 or S6c in either serum-free, or together with 0.5% serum. Cells were collected by trypsin treatment and counted. Data are means Ϯ SE for three independent experiments, performed in sextuplicate. *P Ͻ 0.05, **P Ͻ 0.001 compared with control. described above for DNA synthesis. Incubation was stopped after 72 h. Cells were subsequently trypsinized and counted with a haemocytometer, and viable cells were assessed by Trypan Blue exclusion. Six replicate wells were used for each test condition in each experiment.
Statistical analysis
Data are presented as mean Ϯ SE. Each experiment was repeated at least three times. Data was analysed using analysis of variance (ANOVA) and Student's t-test for multiple comparisons. P Ͻ 0.05 was considered to be significant. Figure 2 shows the growth of myometrial cells in the presence of either 0.5 or 10% FCS which caused a 4-and a 7-fold increase in DNA synthesis respectively compared with serumfree conditions. In the absence of serum, ET-1 at a concentration of 100 nM induced a significant increase in DNA synthesis (168% of the serum-free control) as measured by [ 3 H]-thymidine incorporation. The mitogenic effect of ET-1 was also demonstrated by an increase in cell numbers. In the presence of 0.5% FCS, ET-1 exhibited a dose-dependent DNA synthesis increase, with maximal stimulation (142% of the 0.5% FCS control) occurring at 100 nM ET-1 (Figure 3) . The concomitant increase in cell counts only reached statistical significance at 100 nM ET-1. Under the same conditions, ET-3 and S6c had no significant effect on either [ 3 H]-thymidine incorporation or cell number (Figure 2 ). There were no differences in any of these responses, between myometrial 35 cells derived from the proliferative phase of the menstrual cycle and those from the secretory phase.
Results
Effect of ET isopeptides and sarafotoxin 6c on DNA synthesis and cell growth in human myometrial cells
Characterization of the ET receptor subtype mediating mitogenesis
The effects of ET receptor antagonists were evaluated in order to further identify the subtype of receptor involved in the proliferative response mediated by ET-1. The selective ET A receptor antagonists BQ 123 and FR 139317 (0.1-10 µM) produced concentration-dependent inhibition of the increase in [ 3 H]-thymidine incorporation induced in response to 100 nM ET-1, with complete inhibition observed at 10 µM (Figure 4) . However, IRL 1038, an ET B receptor antagonist, failed to inhibit the ET-1-mediated increase in DNA synthesis at concentrations up to 10 µM. No antagonist (BQ 123, FR 139317 or IRL 1038) present at concentrations as high as 10 µM had any effect on cell growth under basal conditions (serum-free or 0.5% FCS conditions).
Effect of Bordetella pertussis toxin (PTX) on ET-1-induced DNA synthesis
The pretreatment of cells with PTX (0.5 µg/ml) for 24 h completely inhibited [ 3 H]-thymidine incorporation in response to 100 nM ET-1 in serum-free medium or 0.5% FCS supplemented medium ( Figure 5 ). The addition of PTX alone in serum-free medium had no significant effect on [ 3 H]-thymidine incorporation. When the cells were maintained in 0.5% FCS and 10% FCS, preincubation in PTX led to significant inhibition of [ 3 H]-thymidine incorporation of 22 and 65% respectively.
Role of growth factors in ET-1-induced DNA synthesis
We initially compared the effects of IGF-1, IGF-2, EGF and insulin on [ 3 H]-thymidine incorporation in myometrial cells which had been cultured in serum-free conditions or in 0.5% FCS (Figure 6 ). EGF (1-20 nM) stimulated [ 3 H]-thymidine incorporation in a concentration-dependent manner in the absence of serum (data not shown). The maximum effect obtained at 15 nM EGF was~280% of unstimulated serumfree control. The same conditions were required for IGF-1 (15 nM), IGF-2 (15 nM) and insulin (100 nM) in order to observe a significant increase in [ 3 H]-thymidine incorporation, with maximal effects of 196, 170 and 127% of the serum-free control respectively. When similar experiments were performed in medium containing 0.5% FCS, none of the growth factors (IGF-1, IGF-2 and insulin) caused significant stimulation of DNA synthesis. Only the addition of EGF (15 nM) caused significant stimulation of DNA synthesis (~119% of the 0.5% FCS control), which was lower than that obtained in serumfree medium. When co-incubated together with ET-1, none of the growth factors had any significant effect on the stimulated mitogenic response to ET-1 in myometrial cells maintained in the absence of serum. In contrast, if the cells were cultured in the presence of 0.5% FCS, the addition of IGF-1, IGF-2, EGF or insulin significantly diminished the increase in DNA synthesis which occurred in response to ET-1.
Discussion
These results demonstrate that ET-1 alone, in the absence of other growth-promoting agents, can induce DNA synthesis and cell proliferation in cultured human myometrial cells. Both the mitogenic and proliferative responses of ET-1 are mediated by selective stimulation of the ET A receptor. This conclusion is based on the finding that ET-1, but not ET-3, was an efficient stimulator of [ 3 H]-thymidine incorporation and cell number, which is consistent with the relative isopeptide rank order binding affinities for ET A receptors (Arai et al., 1990) . In addition, two selective ET A antagonists, BQ 123 and FR 139317, blocked the increase in [ 3 H]-thymidine uptake in response to ET-1.
The failure of ET B agonist S6c and selective ET B antagonist IRL 1038 to increase [ 3 H]-thymidine incorporation argues against an ET B receptor being linked to these proliferative responses. Further evidence for the absence of an ET B receptor in mediating mitogenic signaling by ET-1 is provided by the fact that we were unable to detect ET B receptors in human myometrial cells cultured in either subconfluent conditions (unpublished results) or in confluent conditions (Héluy et al., 1995b) . Furthermore, Maggi et al. (1994) , demonstrated that only ET A receptors mediated an increase in intracellular calcium in cultured human myometrial cells. All these findings support the action of a mitogenic effect of ET-1 in numerous cell types, which is generally transduced by the ET A receptor (Battistini et al., 1993) . To our knowledge, this is the first demonstration of ET A receptor involvement in human myometrial cell proliferation.
Moreover, our data support a role for PTX-sensitive Gproteins in stimulation of [ 3 H]-thymidine incorporation by ET-1 in cultured human myometrial cells. PTX uncouples the G i family of G proteins from membrane receptors by catalysing ADP ribosylation of their α-subunits, and inhibits the proliferation of various cell types including fibroblasts, epithelial and Figure 5 . Effect of pertussis toxin (PTX) on endothelin-1 (ET-1)-induced DNA synthesis by human myometrial cells. Quiescent cells were incubated for 48 h with 100 nM ET-1 in either serum-free medium or, medium containing 0.5 or 10% serum, and [ 3 H]-thymidine incorporation was determined as in the Materials and methods section. Where indicated, cells were preteated with PTX (0.5 µg/ml) for 24 h. Data are given as means Ϯ SE for three independent experiments performed in triplicate. *P Ͻ 0.05 compared with control. Figure 6 . Effects of endothelin-1 (ET-1) and growth factors on DNA synthesis by human myometrial cells. Quiescent cells were incubated for 48 h with 100 nM ET-1 in either serum-free or 0.5% serum, and [ 3 H]-thymidine incorporation was determined as in the Materials and methods section. Where indicated, cells were co-incubated with 15 nM insulin-like growth factor (IGF-1), IGF-2, epidermal growth factor (EGF) or 100 nM insulin. Data are given as means Ϯ SE of five independent experiments performed in triplicate. *P Ͻ 0.05 compared with control; ϩP Ͻ 0.05 compared with ET-1. myeloid cells (Murayama and Ui, 1987) . More recently, Hermouet et al. (1996) reported that inactivation of G i2 protein can inhibit malignant cell proliferation. It is not known whether ET-1, which binds to G-protein-coupled receptors stimulates mitogenesis by pathways similar to those which operate for serum-induced proliferation. Due to the significant decrease in DNA synthesis observed after preincubation of myometrial cells with PTX in the presence of 0.5 or 10% FCS, we suggest that serum contains some growth factors that bind to the Gprotein to initiate mitogenic signalling. Previous studies have documented that human myometrium expresses two PTXsensitive G proteins (Gi 1,2 and Gi 3 ), as indicated by immunodetection and the observed inhibition of the increase in inositol phosphate induced by ET-1 following preincubation with PTX (Zhumbil et al., 1994; Héluy et al., 1995b) . However, we have no direct evidence for involvement of these G-proteins in the response of myometrial cells to ET-1 or serum.
Numerous reports have demonstrated that ET-1 is a comitogen in vascular smooth muscle cells (VSMC) in the presence of serum or growth factors (Weissberg et al., 1990; Zamora et al., 1993) . This contrasts with the absence of both serum dependence and a requirement for growth factors in order to elicit an ET-1-induced growth response in myometrial cells. Weissberg et al. (1990) also suggested that cultured VSMC can secrete peptide growth factors that may act as endogenous mitogens. The expression of peptide growth factors and EGF and IGF receptors in myometrial cells in culture has also been described (Rossi et al., 1992; Tang et al., 1994) . In our study, we showed that IGF-1, IGF-2, EGF and insulin are individually able to induce DNA synthesis under serum-free culture conditions. These findings are in agreement with a previous report (Tang et al., 1994) , which showed that IGF-1 and EGF elicit a mitogenic response in human myometrial cells grown in serum-free conditions. We found that none of the growth factors tested was a powerful mitogen in human myometrial cells, since a concentration of 15 nM was required to obtain a significant effect on [ 3 H]-thymidine incorporation. Interestingly, ET-1 was unable to increase the level of DNA synthesis induced by several growth factors. In the presence of a serum concentration of 0.5%, EGF alone was found to significantly increase [ 3 H]-thymidine incorporation, although its mitogenic action was weaker than in the absence of serum. Tang et al. (1994) were also unable to demonstrate a proliferative effect of IGFs in human myometrial cells in culture, whereas Fayed et al. (1989) reported that DNA synthesis was stimulated by EGF and insulin. Growth factors were able to reduce ET-1-induced DNA synthesis when myometrial cells were grown in medium containing 0.5% serum; this is consistent with the fact that the stimulating proliferative effect of ET-1 is slightly decreased for myometrial cells cultured in the presence of 0.5% serum, in comparison with culture in the absence of serum. Negative modulation of growth of VSMC by both ET-1 and EGF has been reported by Janakidevi et al. (1992) , who suggested that ET-1 caused a down-regulation of the EGF receptor via PKC activation. However, the exact mechanism of synergy between serum, growth factors and ET-1 in myometrial cells is presently unknown. One possibility is that serum-derived growth factors permit growth of human myometrial cells and stimulate one or more signalling pathways that decrease responsiveness to exogenously administered growth factors.
Another possibility is that, under our culture conditions, the myometrial cells are not in an intensely proliferating phenotypic state. Battistini et al. (1993) reported that variations in phenotypic state, culture techniques or cell density of VSMC could modulate the mitogenic activity of ET-1. The usefulness of passaged cells as a model capable of predicting in-vivo events is dependent upon the maintenance of phenotypic characteristics of the differentiated state. The human myometrial cells used in our experiments were grown from myometrial explants to ensure homogeneity of the cell type. They were used only after 3 days of serum deprivation in order to observe the maximal expression of two markers of smooth muscle phenotype, α-actin and desmin (Cavaillé et al., 1995) . Under similar conditions of culture, the expression of these proteins was found to be preserved for at least 12 passages, as were the mitogenic properties of ET-1, and peptide growth factors were observed in myometrial cells subcultured between the third and ninth passages.
Since human endometrial cells in culture synthesize and release ET-1 (Kubota et al., 1995) and peptide growth factors (Tang et al., 1994) in a manner which varies with the stage of the menstrual cycle, we chose to examine only the external layer of the uterine smooth muscle so as to avoid any possible hormonal influence on growth properties. A lack of hormonal influence was demonstrated by the absence of menstrual cycle stage-dependence observed for the mitogenic action of ET-1 and peptide growth factors in myometrial cells in culture. These results agree with the previous work of Schiff et al. (1993) , who reported similar ET binding properties in human myometrium obtained from the secretory and the proliferative phases of the menstrual cycle. However, it is possible that when released from endometrial cells, ET-1 may act in a paracrine manner on adjacent uterine smooth muscle cells, with both contractile and mitogenic effects. Indeed, similar ET A receptors associated with activation of G-proteins are involved in ET-1-induced human uterine contraction as well as in ET-1-regulated growth of myometrial cells in culture.
Although the physiological function of ET-1 in human myometrium remains unclear, the present study suggests that ET-1 may also contribute to the processes of hypertrophy and hyperplasia which occur in the uterus throughout pregnancy. Since ET-1 can exert a negative control on DNA synthesis in the presence of peptide growth factors and serum, we postulate the existence of a mechanism by which ET-1 acts as a regulator of growth factor activity in myometrial cells. Loss of this negative feedback regulation may explain certain pathologies, including leiomyomas which involve abnormal myometrial cell growth and proliferation. Although leiomyomas are one of the most common gynaecological tumours to be found, the factors involved in their initial development, their growth and regression remain poorly understood. In addition to ovarian steroids, endogenous expression of growth factors (IGF, EGF and transforming growth factor β) has been implicated in the development of leiomyomata (Fayed et al., 1989; HarrisonWoolrych et al., 1994; Dou et al.., 1996) . Since only ET A receptors are present in leiomyomas (Breuiller-Fouché et al., 1997) , our study raises the question of the role of ET-1 in the etiology of such disease. Therefore, agents that selectively block ET A receptors may be useful in further studying the molecular interactions and the signaling pathways by which ET-1 and its receptors regulate growth of uterine smooth muscle.
